Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Drug Discovery > 2026 Vol. 1 > No. 2 > 100032
Next Article Previous Article
LETTER   Open Access     Cite

The oligonucleotide therapeutics boom: FDA approvals from 2021 to 2025 and emerging innovation in drug discovery

  • 1.

    Stanford Bioengineering Department, Shriram Center, Stanford University, Stanford, CA 94305, USA

  • 2.

    Advanced Drug Delivery and Regenerative Biomaterials Laboratory, Cardiovascular Institute, Department of Medicine, Stanford University, Stanford, CA 94305, USA

More Information
  • Corresponding author: liuqiang_1844@hotmail.com
  • Received Date:  May 29, 2026
    Accepted Date:  July 05, 2026
    Published Online:  July 09, 2026
The Innovation Drug Discovery  1(2),  https://doi.org/10.59717/j.xinn-drugdisc.2026.100032  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Chen, L., Xu, J., Li, J., et al. (2026). Therapeutic oligonucleotides revisited: Focus on siRNA and antisense technologies. Innov. Drug Discov. 1:100007. DOI:10.59717/j.xinn-drugdisc.2026.100007

    View in Article CrossRef Google Scholar

    [2] Lu J., Lehn J., Sun A., et al. (2026). The Innovation Drug Discovery: An international journal of drug discovery science. Innov. Drug Discov. 1:100001. DOI:10.59717/j.xinn-drugdisc.2026.100001

    View in Article CrossRef Google Scholar

    [3] Lehn J., Chen S., Lu J., et al. (2026). Multidisciplinary convergence drives next-generation drug discovery: A new paradigm. Innov. Drug Discov. 1:100002. DOI:10.59717/j.xinn-drugdisc.2026.100002

    View in Article CrossRef Google Scholar

    [4] U.S. Food and Drug Administration. (2024). Novel Drug Approvals for 2021 and 2022. FDA. Updated 2024

    View in Article Google Scholar

    [5] U.S. Food and Drug Administration. (2025). Novel Drug Approvals for 2023 and 2024. FDA. Updated 2025

    View in Article Google Scholar

    [6] U.S. Food and Drug Administration. (2026). Advancing Health Through Innovation: New Drug Therapy Approvals 2025. FDA

    View in Article Google Scholar

    [7] Egli, M., Manoharan, M. (2023). Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res. 51:2529−2573. DOI:10.1093/nar/gkad067

    View in Article CrossRef Google Scholar

    [8] Liu, M., Wang, Y., Zhang, Y., et al. (2025). Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines. Signal Transduct. Target. Ther. 10:73. DOI:10.1038/s41392-024-02112-8

    View in Article CrossRef Google Scholar

    [9] U.S. Food and Drug Administration. (2026). Novel Drug Approvals for 2026. FDA. Current as of May 1:2026

    View in Article Google Scholar

    [10] U.S. Food and Drug Administration. (2026). Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause. Draft Guidance. FDA

    View in Article Google Scholar

    • Cited by

  • Cite this article:

    Yam A. and Liu Q. (2026). The oligonucleotide therapeutics boom: FDA approvals from 2021 to 2025 and emerging innovation in drug discovery. The Innovation Drug Discovery 1:100032. https://doi.org/10.59717/j.xinn-drugdisc.2026.100032
    Yam A. and Liu Q. (2026). The oligonucleotide therapeutics boom: FDA approvals from 2021 to 2025 and emerging innovation in drug discovery. The Innovation Drug Discovery 1:100032. https://doi.org/10.59717/j.xinn-drugdisc.2026.100032

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(574) PDF downloads(443)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.